Science & Technology

Clinical Trial Aims to Develop New Methods to Restore Speech with Brain-Computer Interface

(SACRAMENTO) UC Davis Health is recruiting people for a clinical trial with the goal of building a “neurological prosthesis” for restoring speech to people who have lost — or are losing — the ability to speak. The research is aimed at people who have neurological injuries or progressive neurological diseases, such as spinal cord injury, stroke and amyotrophic lateral sclerosis (ALS).

UC Davis Magazine Feature Article: Changing Minds

UC Davis researchers are bringing the benefits of drugs like LSD and cannabis to light. They may be the next big thing in pharmaceuticals for treating a range of problems like depression and anxiety.

For decades, possession and use of drugs like LSD and cannabis has come with a threat of prosecution and jail time. But in the past few years, researchers have started taking a closer look at these compounds, finding potential for new treatments for psychiatric and central nervous system problems such as seizures, depression, anxiety and post-traumatic stress disorder.

UC Davis Neuro Leaders Featured in "Enhancing Brain Health and Neural Performance" Session at 2022 Research Expo (Watch Video)

(DAVIS) On May 11, 2022, over 400 people from the UC Davis research community came together for the annual Research Expo. The event showcased the latest research-related insight, resources, opportunities, and tools to help researchers advance their programs and extend their impact. This year’s event included presentations, exhibits, workshops, and opportunities to network with potential collaborators.

 

$2.7M Grant to UC Davis to Find New Addiction Treatments Related to Psychedelics

 

Evidence from human and animal testing suggests the brain-altering effects of psychedelics could be repurposed for treating addiction. 

Now, researchers at the University of California, Davis, and the University of Colorado Anschutz Medical Campus plan to screen hundreds of compounds to discover new, nonhallucinogenic treatments for substance use disorders. The research is funded by a $2.7 million grant from the National Institute on Drug Abuse, part of the National Institutes of Health.